BioSpace News Archive

Infinity Laboratories is thrilled to officially unveil its new brand identity at the AAPS 2023 PharmaSci 360 Annual Meeting from October 22nd to the 25th in Orlando, Florida.

Celltrion Group announced that the merger agreement between Celltrion, Inc. and Celltrion Healthcare Co., Ltd. was approved at the extraordinary general meeting of shareholders of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.

Medigene AG presents data showing significantly enhanced T cell activity when combining the PD1-41BB costimulatory switch protein with recombinant T cell receptors not only when directed at the cancer-testis antigen New York esophageal squamous cell carcinoma-1 /L Antigen Family Member-1a, but also, presented here for the first time, against the neoantigen mutant Kirsten rat sarcoma virus G12V at the ESMO Congress 2023 held October 20-24, 2023, in Madrid, Spain.

CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404, a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Mindray, a global leader in medical devices and solutions, introduces high-sensitivity troponin I and NT-proBNP cardiac biomarkers.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.

Bicara Therapeutics today announced the presentation of updated, positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101, a first-in-class bifunctional EGFR/TGF-β antibody, at the European Society for Medical Oncology (ESMO) Congress 2023.

Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2 clinical trial of VK2735, the company’s wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (“Justera” or the “Company”) is actively evaluating the possibility of resuming its COVID-19 testing operations, driven by a surge in interest from the film and production industries.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 (“CD1") resulting in an expected interest saving of $569,868.